文献速递乳腺技术与安全USMR

COVID-19 时代的腋窝淋巴结病:放射科医生需要了解的内容

Axillary Lymphadenopathy in the COVID-19 Era: What the Radiologist Needs to Know.
PubMed 文献 · Radiographics · 2022-08-26

本文综述了 mRNA COVID-19 疫苗相关腋窝淋巴结病的影像学评估与管理。重点包括腋窝解剖和淋巴引流、超声基于皮质和门部形态的淋巴结分类、疫苗接种日期和侧别的记录、以及不断更新的指南推荐。对于新诊断乳腺癌患者,不应因接种疫苗而推迟影像检查;对于复杂病例,组织采样和多学科讨论仍有价值。

要点

  • 超声是评估腋窝淋巴结的关键方法,基于皮质和门部形态可预测转移性疾病。
  • 应记录疫苗接种日期和侧别,疫苗剂量尽可能接种于原发恶性肿瘤对侧。
  • 新诊断乳腺癌患者有紧急临床指征或治疗计划时,不应推迟影像检查。

关键影像表现/征象

  • 超声基于淋巴结皮质和门部形态对腋窝淋巴结进行分类,可预测转移性疾病。
  • 疫苗相关良性反应性淋巴结病需与恶性病因鉴别。
  • 理解腋窝解剖和淋巴引流是放射学评估腋窝的关键。

诊断标准与关键数值

  • 超声基于皮质和门部形态分类腋窝淋巴结以预测转移性疾病,具体分级标准未在摘要中报告。
  • 指南推荐记录疫苗接种日期和侧别,疫苗剂量尽可能接种于原发恶性肿瘤对侧。
  • 指南推荐不应因接种疫苗而推迟有紧急临床指征或新诊断乳腺癌治疗计划患者的影像检查。
  • 风险分层方法推荐结合疫苗接种时间和患者总体转移风险解读淋巴结病。
  • 活动性乳腺癌治疗前或治疗期间患者应采用标准影像方案,无论疫苗接种状态。

临床应用与阅片要点

  • 日常阅片应关注腋窝淋巴结皮质和门部形态,结合疫苗接种史判断反应性增生可能。
  • 报告应记录疫苗接种日期和侧别,便于后续对比。
  • 对新诊断乳腺癌患者,不应因近期接种疫苗而推迟必要影像检查。
  • 随访中出现淋巴结增大、MRI 评估病变范围或新辅助治疗反应等复杂情况时,建议组织采样和多学科讨论。

局限性

  • 本文为综述,未报告系统检索策略和纳入文献数量。
  • 指南推荐随经验积累不断更新,具体阈值和分级标准未在摘要中详述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Axillary lymphadenopathy caused by the high immunogenicity of messenger RNA (mRNA) COVID-19 vaccines presents radiologists with new diagnostic dilemmas in differentiating vaccine-related benign reactive lymphadenopathy from that due to malignant causes. Understanding axillary anatomy and lymphatic drainage is key to radiologic evaluation of the axilla. US plays a critical role in evaluation and classification of axillary lymph nodes on the basis of their cortical and hilar morphology, which allows prediction of metastatic disease. Guidelines for evaluation and management of axillary lymphadenopathy continue to evolve as radiologists gain more experience with axillary lymphadenopathy related to COVID-19 vaccines. General guidelines recommend documenting vaccination dates and laterality and administering all vaccine doses contralateral to the site of primary malignancy whenever applicable. Guidelines also recommend against postponing imaging for urgent clinical indications or for treatment planning in patients with newly diagnosed breast cancer. Although conservative management approaches to axillary lymphadenopathy initially recommended universal short-interval imaging follow-up, updates to those approaches as well as risk-stratified approaches recommend interpreting lymphadenopathy in the context of both vaccination timing and the patient's overall risk of metastatic disease. Patients with active breast cancer in the pretreatment or peritreatment phase should be evaluated with standard imaging protocols regardless of vaccination status. Tissue sampling and multidisciplinary discussion remain useful in management of complex cases, including increasing lymphadenopathy at follow-up imaging, MRI evaluation of extent of disease, response to neoadjuvant treatment, and potentially confounding cases. An invited commentary by Weinstein is available online. ©RSNA, 2022.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Zhang, Ahn, Hayes, et al. Axillary Lymphadenopathy in the COVID-19 Era: What the Radiologist Needs to Know. Radiographics. 2022. PMID: 36018786. doi:10.1148/rg.220045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。